ReviewAnnals of translational medicine2019
Is there an optimal "door to cath time" in the treatment of acute pulmonary embolism with catheter-directed thrombolysis?
Review in Annals of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Early versus delayed EKOS thrombolysis in intermediate-high risk pulmonary embolism: a retrospective multicentre analysis.Open heart · 2026Article
- Acute pulmonary embolism: a paradigm shift in interventional treatment and interdisciplinary care?European radiology · 2025Review
- Recent advances in risk stratification and treatment of acute pulmonary embolism.World journal of cardiology · 2025Review
- Early versus delayed catheter-based therapies in patients hospitalised with acute pulmonary embolism.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025Article
- Rethinking Pulmonary Embolism Management with an Interventional Perspective.Journal of clinical medicine · 2025Review
- Comparison of 30-Day Readmission Between Early and Late Catheter Directed Thrombolysis for Acute Pulmonary Embolism in the United States.Journal of cardiovascular development and disease · 2025Article
- Standardized Data Elements for Patients With Acute Pulmonary Embolism: A Consensus Report From the Pulmonary Embolism Research Collaborative.Circulation · 2024Review
- Percutaneous interventions for pulmonary embolism.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2024Review
- Article
- [Ultrasound-accelerated thrombolysis. Initial experience in patients with contraindications to systemic thrombolysis].Revista medica del Instituto Mexicano del Seguro Social · 2023Review
- Impact of Time to Intervention on Catheter-Directed Therapy for Pulmonary Embolism.Critical care explorations · 2023Article
- Outcomes of Surgical and Mechanical Thrombectomy in Massive Saddle Pulmonary Embolism: A National Perspective.Cureus · 2022Article
- Direct versus conventional anticoagulants for treatment of cancer associated thrombosis: a pooled and interaction analysis between observational studies and randomized clinical trials.Annals of translational medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ultrasound assisted catheter-directed thrombolysis (UACT) is a relatively novel approach to treating acute pulmonary embolism (PE). It is an alternative to systemic thrombolysis with good success rates and low reported in-hospital mortality, and low rates of procedure-related major and minor bleeding. Since UACT received FDA approval for the treatment of PE in 2014, there is paucity of data regarding the optimal timing of initiation of the procedure after the initial diagnosis is made. We reviewed the available literature regarding UACT for acute PE and found six studies that included time to procedure. Based on our review, patients may benefit from early (<24-48 h after presentation) rather than delayed (>48 h) initiation. Early initiation of therapy has shown to improve pulmonary arterial pressures, right ventricular (RV) to left ventricular (LV) ratios, with low rates of bleeding and low post procedural and in hospital mortality. However, further studies are required to confirm these findings and establish the appropriate timeline for initiation of UACT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.